Loading...
•
Dec 31, 2020
UroGen Q4 2020 Earnings Report
UroGen reported Q4 2020 financial results, highlighted by Jelmyto net product revenue of $8.0 million and the initiation of the ATLAS Phase III trial for UGN-102.
Key Takeaways
UroGen Pharma reported financial results for the fourth quarter and full year ended December 31, 2020. The company achieved Jelmyto net product revenue of $8.0 million for the fourth quarter. The Phase 3 ATLAS trial for UGN-102 was initiated and is actively enrolling patients.
Achieved Jelmyto net product revenue of $8.0 million for the fourth quarter of 2020.
Initiated ATLAS Phase III trial for UGN-102 and actively enrolling patients with low-grade intermediate risk NMIBC.
Expanded immuno-oncology pipeline with strategic research collaborations.
Strategic funding provides additional capital to support continued Jelmyto launch and UGN 102 program.
UroGen
UroGen
UroGen Revenue by Segment
Revenue by Segment
JELMYTO Revenue
CapyFin.com Forward Guidance
The Company anticipates operating expenses in the range of $155 to $170 million, including non-cash share-based compensation expense of $24 to $28 million, subject to market conditions.